Announcements Trials

Browse Landscape

Phase

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 11 Gastrointestinal 10 Thoracic 4 Sarcoma 2 Lymphoid 2 Gynecologic 2 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Head & Neck 1 Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 390 pembrolizumab 325 Prednisone 284 Gemcitabine 273 enzalutamide 254 Radiotherapy 251 Nivolumab 247 Magnetic Resonance Spectroscopy 247 Cisplatin 209 Abiraterone Acetate 197 Radiosurgery 184 Leuprolide 182 Sunitinib 169 Carboplatin 161 bicalutamide 148 Goserelin 145 Androgen Antagonists 142 Specimen Handling 138 Ipilimumab 128 Paclitaxel 125 Cyclophosphamide 116 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110 Bevacizumab 109 Everolimus 107 apalutamide 98 cabozantinib 97 abiraterone 97 Sorafenib 97 atezolizumab 96 Radiation 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Enoxaparin × Genitourinary × Clear all

NCT06243510 2026-01-28

CARE

Abramson Cancer Center at Penn Medicine

Phase NA Enrolling by invitation

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡